-
平臺(tái)編號(hào)：bio-68248
-
國際編號(hào)：CRL-11181?
-
細(xì)胞信息： L-alpha-2C L-cells
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
L-alpha-2C L-cells
年限：100 days
數(shù)量：大量
細(xì)胞形態(tài)：成纖維樣
是否是腫瘤細(xì)胞：0
物種來源：小鼠
ATCC Number：CRL-11181?
相關(guān)疾?。赫?br /> 生長狀態(tài)：貼壁生長
運(yùn)輸方式：凍存運(yùn)輸
組織來源：subcutaneous connective tissue; areolar and adipose
規(guī)格：0.5mg Designations: L-alpha-2C L-cells
Depositors: ?Synaptic Pharmaceutical Corporation
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Mus musculus
Morphology:fibroblast
Source: Tissue: subcutaneous connective tissue; areolar and adipose
Disease: normal
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:human adrenergic alpha2C, expressed
Age: 100 days
Gender: male
Comments:This line is a derivative of L-M(TK-) (see ATCC CCL-1.3 ) that is stably transfected with the gene for the human adrenergic alpha2C receptor.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Two to three times weekly
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
parental cell line:ATCC CCL-1.3
References: 4474: Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995
71147: Lagu B, et al. Morpholinone and morpholine derivatives and uses thereof. US Patent 6,531,471 dated Mar 11 2003
72023: Gluchowski C, et al. Use of .alpha.1C specific compounds to treat benign prostatic hyperplasia. US Patent 6,602,888 dated Aug 5 2003
90268: Cui D, et al. Dihydropyrimidines and uses thereof . U.S. Patent 6,680,323 dated Jan 20 2004
數(shù)量：大量
細(xì)胞形態(tài)：成纖維樣
是否是腫瘤細(xì)胞：0
物種來源：小鼠
ATCC Number：CRL-11181?
相關(guān)疾?。赫?br /> 生長狀態(tài)：貼壁生長
運(yùn)輸方式：凍存運(yùn)輸
組織來源：subcutaneous connective tissue; areolar and adipose
規(guī)格：0.5mg Designations: L-alpha-2C L-cells
Depositors: ?Synaptic Pharmaceutical Corporation
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Mus musculus
Morphology:fibroblast
Source: Tissue: subcutaneous connective tissue; areolar and adipose
Disease: normal
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:human adrenergic alpha2C, expressed
Age: 100 days
Gender: male
Comments:This line is a derivative of L-M(TK-) (see ATCC CCL-1.3 ) that is stably transfected with the gene for the human adrenergic alpha2C receptor.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Two to three times weekly
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
parental cell line:ATCC CCL-1.3
References: 4474: Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995
71147: Lagu B, et al. Morpholinone and morpholine derivatives and uses thereof. US Patent 6,531,471 dated Mar 11 2003
72023: Gluchowski C, et al. Use of .alpha.1C specific compounds to treat benign prostatic hyperplasia. US Patent 6,602,888 dated Aug 5 2003
90268: Cui D, et al. Dihydropyrimidines and uses thereof . U.S. Patent 6,680,323 dated Jan 20 2004
